| AIA (n = 19) | ATA (n = 21) | p value | |
| Age (years) | 42.4 (13.3) | 43.6 (12.5) | 0.613 (NS) |
| 41 (31–53) | 43 (36–53) | ||
| Sex (F/M) | 11/8 | 13/8 | 0.967 (NS) |
| Duration of asthma (years) | 7.8 (7.5) | 10.6 (9.4) | 0.328 (NS) |
| 5 (1–11) | 7 (3–18) | ||
| Inhaled steroids (yes/no) | 11/8 | 17/4 | 0.170 (NS) |
| Inhaled steroids (μg/day) | 1690 (712) | 1424 (821) | 0.204 (NS) |
| 1600 (1000–2000) | 1000 (800–1600) | ||
| FEV1 baseline (% predicted) placebo day | 90.4 (10.7) | 90.5 (12.1) | 0.683 (NS) |
| 94.8 (82.5–98.1) | 91.4 (81.5–93.6) | ||
| FEV1 baseline (% predicted) aspirin day | 91.6 (10.8) | 94.1 (12.0) | 0.708 (NS) |
| 93.0 (87.7–98.4) | 94.0 (81.9–100.2) | ||
| FEV1 baseline (% predicted) celecoxib day | 92.4 (12.4) | 90.0 (13.8) | 0.631 (NS) |
| 90.9 (85.7–98.6) | 86.6 (78.0–95.7) | ||
| Total IgE (IU/ml) | 182.3 (229.8) | 206.0 (241.6) | 0.844 (NS) |
| 121 (45.4–226) | 91.9 (39.9–345) | ||
| Skin prick test (n) positive/negative | 8/7 | 9/9 | 0.849 (NS) |
| Blood eosinophil count | 425.4 (328.4) | 356.7 (246.7) | 0.667 (NS) |
| 371 (159–669) | 296 (1164–502) |
Values are expressed as mean (SD) or median (25–75% percentiles).
AIA, aspirin-induced asthma; ATA, aspirin-tolerant asthma; FEV1, forced expiratory volume in 1 s; NS, not significant.